is...Trying to learn the ropes in OTC World is like drinking from a firehose.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
THIS IS A MUST READ
"US Stem Cell Inc (OTCMKTS:USRM) Keeps Rising, Here’s Why"
READ FULL ARTICLE HERE:
https://www.insiderfinancial.com/us-stem-cell-inc-otcmktsusrm-keeps-rising-heres-why/120469/
FROM THE ARTICLE:
"...There is another very good factor that other retail investors may not be aware of right now. The company is being bought by institutional shareholders. These are sophisticated investors, who know very well when the shares of a company are ready to rise. It is always important for the small shareholders to monitor what are the big boys doing. In this case, right now they are buying, and they have been buying from the beginning of 2016. The following institutions own or owned a significant amount of shares in this company:
•TELLURIDE TOO, L.L.C.
•Daniel James Management, Inc.
•FOURTH MAN, LLC
•VIS VIRES GROUP, INC.
Didn’t we tell you that something was going on? We don’t really know whether they invested because they saw a change in the direction of the company or because of the financial figures of the firm, but either way, they’re sitting on big profits right now. In any case, we encourage you to read more information about U.S. Stem Cell Inc. in order to have your own opinion.
The stock price of the company has been in an uptrend. It is at the moment reacting with no news, so we wanted to investigate the company a little further. We figured out that the company reached a deal to sell some assets and a lease agreement with another party that the market may have appreciated. In addition, institutional shareholders have been buying these shares for a long time and maybe other investors are becoming more interested due to this reason. In any case, it seems interesting to be informed about this company and its communications since some shareholders have made big money here."
How Long??? As long as we personally see fit!!!!!!!!!!!!!!!!!!!
"IF?
Are we back to IF ffing it now? IF the K report shows that they are still operating in a huge deficit (my guess). How long should investors wait for more news?"
Thanks for the link...it is a good overview of the industry status. FYI it is NOT a paid PR as suggested...it's a cut and paste of different news sources.
Keep the info flowing...more is better.
SLAM
Wildlife is cranky kind of early today. Hey PPete...Give us some good news today....
SLAM
HERE ARE SOME PAST ARTICLES...FYI
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://theindependentrepublic.com/2017/03/27/analysts-review-on-trending-stock-pharmacyte-biotech-inc-pmcb-growlife-inc-phot-earth-science-tech-inc-etst/&cid=0&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNGO2CoJm3CuCZxITWM0Ay0vW8nKXQ
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://heraldks.com/harsco-hsc-reaches-12-30-after-7-00-down-move-pharmacyte-biotech-pmcb-shorts-decreased-by-9-13/&cid=52779435857361&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNHNSoF9-0TNKaVW-q19VfrPE-Loqg
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://globenewswire.com/news-release/2017/03/22/943094/0/en/PharmaCyte-Biotech-Strengthens-Protection-of-Cancer-Therapy-with-Patent-Filing.html&cid=52779433033552&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNFuCxfEgXrve3aNuQKQX23UWt-C7g
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.mmjobserver.com/pharmacyte-biotech-inc-otcmktspmcb-holds-a-shareholder-call-as-it-promises-to-answer-most-of-the-questions-by-shareholders-and-analysts/9372/&cid=0&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNED67YfHWDsupRnrN3SEc1U8BNOag
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-has-a-fast-track-to-commercialization/120177/&cid=52779424941272&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNEFUhyaHv_YQDmuhe60bXORV4xH6A
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://mmjreporter.com/pharmacyte-biotech-inc-otcmktspmcb-brings-onboard-dr-makowka-on-an-advisory-role-2637.html&cid=0&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNHzNdFUsoC6RSNe5I-fwG7IOHhAHw
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://globenewswire.com/news-release/2017/03/13/934999/0/en/PharmaCyte-Biotech-Names-Dr-Leonard-Makowka-as-Senior-Strategic-Advisor.html&cid=52779419520007&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNHMLpC6Dw2Bqa0OHTm82neeGqSJvw
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://globenewswire.com/news-release/2017/02/21/925912/0/en/PharmaCyte-Biotech-Discusses-Patient-Enrollment-and-TD2-s-Role-in-Upcoming-Clinical-Trial.html&cid=52779392733989&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNENNLTZ1XZgXj2z1j2uOcQ38fdCHQ
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://globenewswire.com/news-release/2017/02/13/916491/0/en/PharmaCyte-Biotech-Moves-Closer-to-Filing-IND-with-Naming-of-Comparator-Arm-for-Upcoming-Clinical-Trial-and-Discusses-Pivotal-Trial-Opportunity.html&cid=52779381781504&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNEAXEdufVZZ3m97b3Be20anFD30nA
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-is-going-after-the-gold-standard-pancreatic-cancer-treatment/119321/&cid=52779365751617&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNFlAoV-Owxfwr7xTzSPeylLkcU-ZQ
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://oracledispatch.com/2017/01/28/keeping-eye-pharmacyte-biotech-inc-otcmktspmcb/&cid=0&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNHfioJTGYuMpdRizgaEG6pdqx3Ylg
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://oracledispatch.com/2017/01/06/watch-pharmacyte-biotech-inc-otcmktspmcb/&cid=52779335680415&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNGdr7dcC0gyHMhokBO9ehBO-sCqJA
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-why-its-up-and-what-were-looking-for-next/118805/&cid=52779322578517&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNHvQLjGPW82q6iMUevtcpjtG5N1oQ
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://oracledispatch.com/2016/12/22/pharmacyte-biotech-inc-otcmktspmcb-keeps-rolling-along/&cid=0&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNEPVuyBQUcdAs-W2GnUglQGCH5lhw
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.mmjobserver.com/good-news-pour-in-for-pharmacyte-biotech-inc-otcmktspmcb-marapharm-ventures-inc-otcmktsmrphf-releases-construction-timelines/9021/&cid=52779314259699&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNGB-XkAClTkwGzOnOGQvULIjk5adQ
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-the-future-is-bright/118600/&cid=52779298529329&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNGtY5Gx_8wXHwO2e-HaU_NBsb1pkg
http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-soars-opens-floodgates-for-catalysts/118471/&cid=52779289306927&ei=skjaWNH2MdSLmAHrja_wAQ&usg=AFQjCNHvWQ1hI1DIoqhw3QggAc3_dbwPig
New Breakout Potential for Strikeforce Technologies Inc (OTCMKTS:SFOR)
By Jermaine Farmer -
March 27, 2017
http://oracledispatch.com/2017/03/27/new-breakout-potential-strikeforce-technologies-inc-otcmktssfor/
SLAM
Yet again...TOOOOOOOOO FUNNY
WAY TOOOOOOOO FUNNY
mikman77 Monday, 03/27/17 08:19:03 AM
Re: zatafour post# 146088
Post # of 146101
REVERSE SPLIT IS EVIDENT- OVER 2 BILLION SHARES-BUYERS BEWARE
100% BUY - BAR CHART
100% BUY - BAR CHART
VERY INTERESTED TO SEE THE NEW DIRECTION.....TIC TOCK
SLAM
Fantastic
For the record...I have never heard of any type of new drug/treatment development that did not have an associated risk potential...never. It is sad that anyone would have an adverse reaction to ANY drug/treatment...but it happens. I personally have a family member that has been treated by this method and has had OUTSTANDING results.
""We have treated more than 7,000 patients and we've have had very few adverse events reported. So the safety track record is very strong," Comella says. "We feel very confident about the procedures that we do, and we've had great success in many different indications."
GLTA
SLAM
Thanks BTB...To All, read this post...it is a sticky as well.
SLAM
What's up with the volume?????
HEY PETE...FROM PENNY
Voyage leaves at March 17, 6 am
Vessel Birth at Port of Chennai
THANKS FOR THAT FOLLOW-UP. GLAD TO SEE THE SHIP IS STILL MOVING.
GLTY
SLAM
ZPaul...PRAYING THAT ALL IS WELL. BEST WISHES
Best of all regards,
SLAM
I vote for Dr. Evil!!!!!!!!!!!!!!!!
Agreed...I also liked the other one as well regarding Joint Pain Relief with Dr. Rochman.
GLTA
SLAM
Stem Cell Therapy: Modern Solution to Joint Pain Relief
PR NewswireMarch 06, 2017
PLAINVIEW, N.Y., March 6, 2017 /PRNewswire/ -- Board certified surgeon Dr. Andrew J. Rochman promotes the specialized treatment of Stem Cell Therapy in his private practice in Plainview, NY. The recent wave of positive response from its ability to target a growing number of health conditions has brought increased attention and demand from pain sufferers everywhere- including the Long Island area.
As of the fall of 2016, Dr. Rochman officially opened the Cell Therapy Center of NY (CTCNY) where he focuses on the treatment of osteoarthritis & rheumatoid arthritis, eroded cartilage and joint issues like tennis elbow, jumpers knee and golf elbow. He dedicated his practice to the large population suffering from musculoskeletal damage arising from sports injuries or the wear and tear from aging. "We are always seeking a safer and more effective alternative to surgery to battle physiological symptoms with the hopes of giving patients a pain-free life."
Dr. Rochman underwent extensive training from U.S. Stem Cell, Inc. (Sunrise, FLA) - a center for the development of effective cell technologies recognized for treating a variety of diseases and injuries. U.S. Stem Cell's discoveries include multiple cell therapies in various stages of development that repair damaged tissue due to injury or disease. Chief Science Officer Kristin C. Comella, expert in regenerative medicine with a focus on adipose derived stem cells, pioneered stem cell therapies derived from various sources including cord blood, bone marrow and muscle. "By harnessing the body's own healing potential, we may be able to reverse damaged tissue to normal function.... stem cells have the ability to form many types of tissues like bone, cartilage, muscle and even help to reverse some effects that have been caused by damaged tissue," states Ms. Comella.
Dr. Rochman's treatment center has recently seen an influx of patients from Long Island's large athletic and fitness community. President of the Wildwood Warriors triathlon team, John Graziano is one of the many joint and back pain sufferers from sports injuries seeking this alternative pain treatment. "In the world of triathlon, I train- I race- and I live with pain… and lots of it!"
"The potential here is limitless," states Dr. Rochman. "It's actually a simple yet unique form of therapy with the possibilities of doing miraculous things. We found out within the past several years that human beings have stem cells in every tissue of their body and they actually live around the blood vessels." Today's stem cell therapy has been shown to manage and target a wide span of healing possibilities from blood cell diseases to cardiac disorders to autoimmune diseases. "So what we can do now is to extract fat cells from the belly or bone marrow cells and isolate the cells from those damaged tissues... perhaps in the future we can utilize this process to target neurological diseases, heart diseases... and we don't even know where it ends," says Dr. Rochman.
Dr. Andrew J. Rochman is a native New Yorker and a board-certified surgeon. He is a graduate of Colgate University and received his formal medical training from Nordestana University. He is an active member of the American Medical Association, the Medical Society of the State of New York, Nassau County Medical Society and the American College of Phlebology. Dr. Rochman manages several practices in specialized studies such as advanced vein therapy and gallbladder surgery. His current certification is with U.S. Stem Cell, Inc. specializing in cardiovascular treatment through stem cell technology. The Cell Therapy Center of NY is located at 700 Old Country Road, Suite 205 Plainview, NY. For more information, visit: www.celltherapycenterny.com or call 516-280-1333.
Media contact:
Lennard Gettz
148804@email4pr.com
631-553-8748
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-modern-solution-to-joint-pain-relief-300417654.html
Traders News
U.S. Stem Cell, Inc. (OTCMKTS: USRM) Outlook and Review
March 5, 2017
A+ A-
U.S. Stem Cell, Inc. (OTCMKTS: USRM), is engaged into development of effective cell technologies to treat variety of diseases and injuries. USRM’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. The company was founded in 1999 and is based in Florida.
Regenerative medicine is an emerging field for regeneration, repair & replacement of damaged human tissue and organs. The global regenerative medicine market is likely to reach a cumulative valuation of US$7 billion by 2019. USRM’s focus on moving up the value & marketing chain through signing new licensing agreement & entering into partnerships is likely to enrich its business strengths.
The company’s Chief Scientific Officer, Kristin Comella recently published a paper on the Implantation of SVF in patients with Degenerative Disc Disease. The study focused on the implantation of stromal vascular fraction (SVF) in patients suffering from degenerative disc disease. Patients were monitored for a period of 6 months post-treatment, noting considerable decreases in pain and increases in flexion.
USRM is in the process of launching new clinics and programs in the Middle East and China that will feature its technologies, therapies, and products. Also, it signed new licensing agreement with High Rising Group to open clinics throughout the Middle East, with locations in Dubai, Kuwait, and Qatar. Additionally, it entered into a partnership with Hong Kong Yihe Regeneration Medical Technology, to provide Chinese patients direct access to USRM’s treatments and regenerative therapies at its Sunrise, Florida clinic.
USRM’s product specific marketing partnerships with global players is likely to enhances revenue growth prospects for the company given its product development capabilities and marketing network of its partners in different geographies. Notwithstanding USRM positive growth plan, meaningful & sizeable contribution from the same is partially constrained due to large investment requirements and still evolving commercialization pathway for its product pipeline. Also, overseas partnerships might face initial integration/gestational issues.
For 3rd Quarter, USRM’s revenue up by 31% to from $557K in Q3 2015 to $729K in Q3 2016 & Net loss improved 17% from $264K in Q3 2015 to $219K in Q3 2016
About the company:
US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. The company is focused on discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The management believes that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, leading to, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Major divisions:
USRM’s business includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) including development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.
Key differentiating factor:
USRM focusses on harnessing body’s own healing potential, by reversing damaged tissue to normal function. USRM discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle. While most stem cell companies use one particular cell type to treat a variety of diseases, USRM utilizes various cell types to treat different diseases. Management believes that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
About the industry:
Regenerative medicine is an emerging field for regeneration, repair & replacement of damaged human tissue and organs. Due to its critical contribution, regenerative medicine is becoming excessively popular in the treatment of neurological, cardiovascular, musculoskeletal, and orthopedic conditions. Bone and joint conditions are among the frontline applications of regenerative medicine. According to a study, global regenerative medicine market is likely to reach a cumulative valuation of US$7 billion by 2019.
Recent developments:
During Jan’17, Chief Scientific Officer, Kristin Comella published a paper on “Effects of the intradiscal implantation of stromal vascular fraction plus platelet rich plasma in patients with degenerative disc disease”. The study focused on implantation of stromal vascular fraction (SVF) in patients suffering from degenerative disc disease. Patients underwent a local tumescent liposuction procedure to remove approximately 60 ml of fat tissue from the abdomen. The fat was separated to isolate the SVF and the cells were delivered directly into the damage discs. Patients were monitored for a period of 6 months post-treatment, noting considerable decreases in pain and increases in flexion.
Prior to this, USRM signed a new licensing agreement with High Rising Group to open clinics throughout the Middle East, with locations in Dubai, Kuwait, and Qatar. They will be treating patients suffering from chronic conditions, like COPD and Parkinson’s, with the goal of transforming their lives by helping them with these debilitating conditions.
Additionally, they also entered into a partnership with Hong Kong Yihe Regeneration Medical Technology, to provide Chinese patients direct access to USRM’s treatments and regenerative therapies at its Sunrise, Florida clinic.
Outlook over near to medium term:
Management maintains its stance that revenues and their associated cash in-flows generated from its businesses will, over time, provide funds to support clinical development activities as they do today for its general business operations. They believe the combination of its own therapeutics pipeline combined with its revenue generating capabilities provides USRM with a unique opportunity for growth and a pathway to profitability.
From an operational perspective, USRM is focusing to continue developing pioneering regenerative medicine techniques and technologies as they work to bring regenerative therapies to patients around the world.
Key Stock Influences
Some key influences that might govern future stock price performance include:
• USRM is still a research and Development Company and its MyoCell product candidate has not received regulatory approval or generated any meaningful revenues and is not expected generate revenues over the near term. Therefore, any positive announcement related with approvals, outcome of ongoing trials, synergies due to partnership efforts could be a temporary trigger for stock performance.
• Over medium to longer term, successful launch & commercialization of existing and future therapeutics products would be critical given the considerable investments undertaken in R&D and infrastructure development during the recent past.
• Given high investments incurred related to the marketing of USRM’s products in different markets, cash drainage in its ongoing R&D activities and uncertainties related to the outcome of recent partnerships, overall return/profitability indicators could remain muted during the initial gestation period. Also, optimal utilization of integration with other global players will be among the key business sensitivities for the company.
• The company is likely to generate substantial net losses and negative cash flow from operations over the near to medium term. Therefore, USRM’s available cash balance might not be sufficient to fund its anticipated level of operations for at least the next twelve months. Therefore, timely arrangement of incremental funding would remain a critical liquidity & financial flexibility factor.
Earnings Review
USRM recognized revenues of $729,813 for three months ended September 30, 2016. These revenues were generated from the sales of kits and equipment, services, MyoCath Catheters, AdipoCell, and laboratory services. It recognized revenues of $557,612 for the three months ended September 30, 2015 from the sale of MyoCath catheters, AdipoCell, physician training, patient studies and laboratory services. The differential in revenue reflected an increase based on the products and services provided.
Operating Metrics & profitability:
Cost of sales was $332,522 and $243,940 in the three month periods ended September 30, 2016 and 2015, respectively. Associated gross margins were $375,651 (53.0%) and $313,672 (56.3%) for the three months periods ended September 30, 2016 and 2015, respectively.
Cash Flow & Balance Sheet:
USRM have generated substantial net losses and negative cash flow from operations since inception and anticipate incurring significant net losses and negative cash flows from operations for the foreseeable future. Historically, company have relied on proceeds from the sale of common stock and dependence on debt to provide the funds necessary to conduct research and development activities and to meet other cash needs. At September 30, 2016, it had cash and cash equivalents totaling $245,991 & working capital deficit as of such date was approximately $6.7 million.
Stock Performance:
On Friday, March 3rd, 17, USRM shares declined by -20.17% to $0.0319 on an average volume of 24.21M shares exchanging hands. Market capitalization is $2.64 million.
The current RSI is 64.3
In the past 52 weeks, shares of USRM have traded as low as $0.00 and as high as $0.35
At $0.0319, shares of USRM are trading above its 50-day moving average (MA) at $0.01 and 200-day MA at $0.01.
The present support and resistance levels for the stock are at $0.0261 & $0.0415 respectively.
*** DRNK NEWS OUT 3-3-2017 ***
Speaking of taking out the trash...GO USRM
I had to look up the word jingoism. Now I will continue waving MY FLAG OF THE UNITED STATES OF AMERICA!!!
ANOTHER NICE HIT....
Nice Hit....
That is true...but the reason I have stayed in this long is because of the heart re-generation that happened a few years back. WOW...IT WAS AMAZING. A 50% PLUS REGENERATION.
GLTA
SLAM
Currently...
10.8m on the bid at .0002
800k on the ask at .0003
GLTY
SLAM
64% average BUY...Barchart...up from 56% yesterday and 46% the day before.
GO CATV
SLAM
I respectfully agree with your costing numbers.
SLAM
Looks like yesterday was fun...looking forward to news and more "fun" today. Best of luck to all that have waited a longggggg time.
SLAM
HH...would you mind posting the possible BO DD again...I have been OOO and have missed that info.
GLTA
SLAM
PETE/Mick & Friends...USRM????
SLAM
Good morning to you as well Pete...fun times ahead!!!
GLTA
SLAM
LOL...love that.
GLTY
SLAM
56% Buy BARCHART Overall Average